Ensemble force changes that result from human cardiac myosin mutations and a small-molecule effector

Area of Science:

• Biochemistry
• Molecular Biology
• Cardiovascular Research

Background:

• Mutations in human β-cardiac myosin cause heart failure and sudden death.
• Understanding myosin's molecular basis is crucial for drug discovery.
• An in vitro assay is needed to measure cardiac myosin's ensemble force.

Purpose of the Study:

• To characterize the ensemble force of human α- and β-cardiac myosin isoforms.
• To investigate the effects of cardiomyopathy-associated mutations (M531R, S532P) on β-cardiac myosin.
• To evaluate omecamtiv mecarbil's effect on cardiac myosin force generation.

Main Methods:

• Utilized a utrophin-based loaded in vitro motility assay.
• Employed novel filament-tracking software for analysis.
• Characterized wild-type and mutant human cardiac myosin isoforms (α and β).

Main Results:

• Human α- and β-cardiac myosin exhibit distinct mechanical and enzymatic phenotypes.
• Mutant β-cardiac myosins (M531R, S532P) display altered force generation.
• Omecamtiv mecarbil was shown to enhance β-cardiac myosin force production.

Conclusions:

• Cardiac myosin isoforms and mutations have unique functional characteristics.
• The developed assay system is suitable for studying myosin function and drug effects.
• Omecamtiv mecarbil demonstrates potential as a therapeutic agent for certain cardiomyopathies.